Scholarlink

<p>Angiogenesis represents a mechanism enabling tumors to evade immune surveillance. This immune escape is mediated, at least in part, by angiogenic factor-induced endothelial cell anergy, which suppresses leukocyte adhesion and infiltration into the tumor microenvironment. Consequently, it is becoming increasingly evident that the efficacy of immunotherapy can be improved by its combination with anti-angiogenic agents. Numerous studies, including clinical trials, have provided proof of this concept. A paper in this issue of <i>Angiogenesis</i> further substantiates this paradigm by demonstrating that normalizing the tumor vasculature and overcoming endothelial cell anergy also ameliorates the activity of CAR T cell therapy. Here, we place these findings into a broader mechanistic context and discuss their implications for combination treatment strategies.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The vascular contribution to immunotherapy success

  • 期刊论文

  • 发表日期：

    2026年3月13日

查看全文
  • Arjan W. Griffioen,
  • Judy R. van Beijnum,
  • Sacha Jacobs,
  • Mattie Cassee,
  • Myra Castel,
  • Patrycja Nowak-Sliwinska

摘要

Angiogenesis represents a mechanism enabling tumors to evade immune surveillance. This immune escape is mediated, at least in part, by angiogenic factor-induced endothelial cell anergy, which suppresses leukocyte adhesion and infiltration into the tumor microenvironment. Consequently, it is becoming increasingly evident that the efficacy of immunotherapy can be improved by its combination with anti-angiogenic agents. Numerous studies, including clinical trials, have provided proof of this concept. A paper in this issue of Angiogenesis further substantiates this paradigm by demonstrating that normalizing the tumor vasculature and overcoming endothelial cell anergy also ameliorates the activity of CAR T cell therapy. Here, we place these findings into a broader mechanistic context and discuss their implications for combination treatment strategies.